Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.

Summary

The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the coronavirus infectious disease (COVID-19).

Timeline

Start

2021-10-15

Primary completion

2022-06-08

Completion

2022-06-08

Outcome

Met primary endpoint

registry analysis (superiority test); Prospekta vs Placebo; p = 0.0016; Wilcoxon (Mann-Whitney) NCT05074888 ↗

Drugs

Indications